Search
A new CAR-T-cell therapy tricks cancer cells with a decoy to increase treatment efficiency in B-cell Acute Lymphoblastic Leukaemia
- OPACC
- Mar 25
- 1 min read
CAR-T cell therapy has significantly improved outcomes for B-ALL patients, but relapse still occurs in over 50% of cases, leaving many with limited treatment options. Ongoing research aims to address this challenge and improve CAR-T therapy effectiveness.
Recent Posts
See AllQuality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
While the overall prevalence of comorbidities at diagnosis in pediatric patients with acute lymphoblastic leukemia (ALL) and...
Comments